주식회사디앤허브
주식회사디앤허브's KOBDi Score is 85.21 as of Sep 2026, up 0.16 points since Apr 2025; it rose in 1 of the 12 monthly updates and never fell. As of Sep 2026 it is ahead of about 90% of companies in its industry, against 90% in Aug 2026 and 90% in Apr 2025. Its strongest position was 91% (May 2025) and its weakest 89% (Dec 2025).
A year earlier, in Aug 2025, its score was 85.05 and it was ahead of about 90% of companies in its industry.
| Sep 2026 | 85.21 | ahead of 90% |
| Aug 2026 | 85.21 | ahead of 90% |
| Jul 2026 | 85.21 | ahead of 90% |
| Jun 2026 | 85.21 | ahead of 90% |
| May 2026 | 85.21 | ahead of 90% |
| Apr 2026 | 85.05 | ahead of 90% |
| Mar 2026 | 85.05 | ahead of 90% |
| Feb 2026 | 85.05 | ahead of 90% |
| Dec 2025 | 85.05 | ahead of 89% |
| Aug 2025 | 85.05 | ahead of 90% |
| Jul 2025 | 85.05 | ahead of 90% |
| May 2025 | 85.05 | ahead of 91% |
| Apr 2025 | 85.05 | ahead of 90% |
Where is 주식회사디앤허브 located?
주식회사디앤허브 is registered at 경기도 포천시 내촌면 오림포1길, South Korea (postal code 11190).
What industry is 주식회사디앤허브 in?
주식회사디앤허브 belongs to Manufacturing › Pharmaceuticals & Biologics › Oriental medicine manufacturing.
What is 주식회사디앤허브's KOBDi Score?
85.21 as of September 2026, ahead of about 90% of companies in its industry.
Who are 주식회사디앤허브's competitors?
Similar companies include HYUN JIN PHARM, Han Kook Sin Yak Pharmaceutical and Epulip Pharmaceutical.


